Daylife Select
A point & click tool to create dynamic content portals. Learn More »
Editor's Picks
There is no pinned content in this Editor's Picks module.
Click here to learn more about content pinning.
-
RESEARCH TRIANGLE PARK, N.C. -- (BUSINESS WIRE) -- CED, a nonprofit organization that promotes entrepreneurial efforts in the Triangle region of N.C. , has announced that it will offer new programming for CED’s 19th annual Biotech 2010... Full Article at Freshnews.com
-
Responsibilities: The department of Pharmaceutical and Device Development has an opening for an engineer to work in the development and commercialization of drug-delivery injection devices for Genentech's protein therapeutics. Full Article at Nature.com
-
The Bothell, WA-based biotech company (NASDAQ: SGEN) said today that half of the 30 patients with diffuse large B-cell lymphoma had their tumors completely or partially go away when they got the company’s experimental antibody, dacetuzumab. Full Article at Xconomy
-
SEATTLE -- (BUSINESS WIRE) -- Seattle Genetics, Inc. Full Article at Freshnews.com
-
NEW ORLEANS -- (BUSINESS WIRE) -- Genentech, Inc. , a wholly owned member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), and Biogen Idec (Nasdaq: BIIB) today announced that three-year follow up of the pivotal Phase III CLL8 trial showed Rituxan plus... Full Article at Freshnews.com
-
GreenBiz.com and Green Impact have partnered to release a new report, "Green Teams: Engaging Employees in Sustainability." Full Article at GreenBiz
-
Genentech, Inc. , a wholly owned member of the Roche Group (OTCQX: RHHBY), and Biogen Idec (NASDAQ: BIIB) today announced that three-year follow up of the pivotal Phase III CLL8 trial showed Rituxan plus fludarabine and cyclophosphamide (FC)... Full Article at Street Insider
-
There was tremendous consolidation in healthcare during the first three quarters. Full Article at The Deal: Blogs
-
In the bicoastal battle for biotechnology executive talent, score three for the Bay State. The region has picked up at least three new biotech CEOs from the San Francisco Bay Area in the past few months. Full Article at Mass High Tech Business News
-
The pharma industry is increasingly focused on peptide and protein therapeutics, particularly true of Roche following its acquisition of Genentech, and consequently technologies that improve their production are in demand. Full Article at InPharmaTechnologist
-
BOTHELL, Wash.--(BUSINESS WIRE)--Dec 1, 2009 - Seattle Genetics, Inc. Full Article at Drugs.com
-
Today Asher Mullard Please Login to read the full article. Full Article at Scrip News
-
MENLO PARK, Calif.--(BUSINESS WIRE)-- McDermott Will & Emery LLP is pleased to welcome Paul De Stefano, one of the nation's elite attorneys in the biotech industry, to its Silicon Valley office. Full Article at Street Insider
-
The month of December has always been a busy period for biotech investors, due to two important events: The annual meeting of American Society of Hematology (ASH) and the San Antonio Breast Cancer Symposium (SABCS). Full Article at iStockAnalyst
-
One of the commonest barriers to innovation is lack of time. People are just too busy doing their day job to spend time trying new things. The common assumption is that working hard and working long hours are good things and sufficient for success. Full Article at BQF Innovation
-
2009-12-02 11:16:53 - Genentech Inc.-Deals & Alliances Report - a new market research report on companiesandmarkets.com product with detailed descriptions of the partner firm where disclosed, partners in other non-product, non-technology... Full Article at PR-Inside.com
-
Doctors may be able use an advanced X-ray called a CT scan to see whether patients with advanced colorectal cancer are responding to treatment with Avastin and chemotherapy, U.S. researchers said on Tuesday. Full Article at The Post Chronicle
-
One of the commonest barriers to innovation is lack of time. People are just too busy doing their day job to spend time trying new things. The common assumption is that working hard and working long hours are good things and sufficient for success. Full Article at Associated Content
-
-- The expected rate of growth in royalty-bearing product sales by PDL's existing licensees; -- The relative mix of royalty-bearing products manufactured and sold outside the U.S. versus manufactured or sold in the U.S. ; -- The ability to... Full Article at Freshnews.com
-
Is the United States in inexorable economic decline, destined to be overshadowed by an emerging Chinese economic superpower? This seems to be a popular view among commentators of various political persuasions. Full Article at American Spectator
About Genentech, Inc.
Wikipedia
There are no results for this module. Edit this module to change the search term used to query Wikipedia
Related Photos
prev
next
-
AP Photo
In this July 10, 2006 file photo, Genentech researcher Mark Nagel works on an experiment in a research laboratory at Genentech headquarters in a South San Francisco, Calif.
View Photo » -
AP Photo
Genentech headquarters in South San Francisco, Calif. seen Friday, March 6, 2009.
View Photo » -
AP Photo
Genentech headquarters in South San Francisco, Calif. seen Friday, March 6, 2009.
View Photo » -
AP Photo
Genentech headquarters in South San Francisco, Calif. seen Friday, March 6, 2009.
View Photo » -
AP Photo
Exterior view of Genentech headquarters in South San Francisco, Calif. , Friday, March 6, 2009.
View Photo » -
AP Photo
Todd Pierce, Genentech Inc.'s chief technology officer, poses for a photo with some of his employees in the company's headquarters in San Francisco, Friday, Dec. 12, 2008.
View Photo » -
AP Photo
Todd Pierce, Genentech Inc.'s chief technology officer, poses for a photo in the company's headquarters in San Francisco, Friday, Dec. 12, 2008.
View Photo » -
Reuters Pictures
A general view shows the plant of Swiss pharmaceutical company Roche and the Rhine River in Basel July 20, 2009. Swiss drugmaker Roche gave a bullish forecast for the next two years after its $47 billion acquisition of Genentech and said it would expand capacity for H1N1 flu drug Tamiflu.
View Photo » -
Reuters Pictures
The logo of Swiss pharmaceutical company Roche is seen at an office building at the company's plant in Basel July 20, 2009.
View Photo » -
Reuters Pictures
A general view shows the plant of Swiss pharmaceutical company Roche and the Rhine River in Basel July 20, 2009. Swiss drugmaker Roche gave a bullish forecast for the next two years after its $47 billion acquisition of Genentech and said it would expand capacity for H1N1 flu drug Tamiflu.
View Photo » -
Reuters Pictures
A general view shows the plant of Swiss pharmaceutical company Roche and the Rhine River in Basel July 20, 2009. Swiss drugmaker Roche gave a bullish forecast for the next two years after its $47 billion acquisition of Genentech and said it would expand capacity for H1N1 flu drug Tamiflu.
View Photo » -
AP Photo
The Aug. 12, 2005 file photo shows the logo of Swiss pharmaceutical company Roche at the headquarters in Basel, Switzerland.
View Photo » -
Reuters Pictures
General view of Swiss pharmaceutical company Roche's general annual shareholders meeting in Basel March 10, 2009.
View Photo » -
Reuters Pictures
Franz Humer (L), chairman of the board and Severin Schwan, CEO of the Swiss pharmaceutical company Roche, speak before the company's general annual shareholders meeting in Basel March 10, 2009.
View Photo » -
Reuters Pictures
Franz Humer, chairman of the board of the Swiss pharmaceutical company Roche, holds a speech during the company's general annual shareholders meeting in Basel March 10, 2009.
View Photo » -
Reuters Pictures
Severin Schwan, CEO of the Swiss pharmaceutical company Roche, attends the company's general annual shareholders meeting in Basel March 10, 2009.
View Photo » -
Reuters Pictures
Severin Schwan, CEO of the Swiss pharmaceutical company Roche, attends the company's general annual shareholders meeting in Basel March 10, 2009.
View Photo » -
Reuters Pictures
Severin Schwan, CEO of the Swiss pharmaceutical company Roche, attends the company's general annual shareholders meeting in Basel March 10, 2009.
View Photo » -
Reuters Pictures
Franz Humer (L) chairman of the board and Severin Schwan, CEO of the Swiss pharmaceutical company Roche, attends the company's general annual shareholders meeting in Basel March 10, 2009.
View Photo » -
Reuters Pictures
Franz Humer, chairman of the board of the Swiss pharmaceutical company Roche, attends the company's general annual shareholders meeting in Basel March 10, 2009.
View Photo » -
Reuters Pictures
Franz Humer, chairman of the board of the Swiss pharmaceutical company Roche, attends the company's general annual shareholders meeting in Basel March 10, 2009.
View Photo » -
Reuters Pictures
Bill Burns, CEO Division of Roche Pharmaceuticals, speaks during an interview in New York February 6, 2009.
View Photo » -
AP Photo
Severin Schwan, CEO of Roche, speaks during an interview with The Associated Press Friday, Feb. 6, 2009, in New York.
View Photo » -
AP Photo
Severin Schwan, CEO of Roche, speaks during an interview with The Associated Press Friday, Feb. 6, 2009, in New York.
View Photo » -
AP Photo
Severin Schwan, CEO of Roche, speaks during an interview with The Associated Press Friday, Feb. 6, 2009, in New York.
View Photo »
AP Photo
Genentech headquarters in South San Francisco, Calif. seen Friday, March 6, 2009.
View Photo »Related Topics
Related Videos
Related Quotes
- Previous
- Next
- 1/10
-
Genentech, a subsidiary of the Swiss drug giant Roche, estimates that 42 House members picked up some of its talking points - 22 Republicans and 20 Democrats ... Rep. Bill Pascrell Jr., a New Jersey Democrat, said: 'I regret that the language was the same. I did not know it was.'
SOURCE: McClatchy -
lobbyists, employed by Genentech and by two Washington law firms, were remarkably successful in getting the statements printed in the Congressional Record under the names of different members of Congress.
SOURCE: Sunlight Foundation -
Now companies like Amgen and Genentech and J & J [Johnson & Johnson] and other companies that you know are doing their logistics work right here from Louisville ... In fact, Genentech, the first investment made outside of the state of California was right here in Louisville and it was right here because...
SOURCE: WFPL -
Now companies like Amgen and Genentech and J & J [Johnson & Johnson] and other companies that you know are doing their logistics work right here from Louisville ... In fact, Genentech, the first investment made outside of the state of California was right here in Louisville and it was right here because...
SOURCE: WFPL -
Peregrine's bavituximab and Cotara products represent the kind of innovation that made my drug development work so exciting and fulfilling at Genentech
SOURCE: Freshnews.com -
The Center and Genentech, Inc. are delighted to recognize Nancy for all that she has done for HDMA and for the community
SOURCE: Medical News Today -
Even with our enterprise business, which we’ve been working hard on for some time, not only is our business accelerating, but I actually personally spoke to a number of our customers, for example, Motorola, Genentech, and Johnson Diversity, getting feedback very strong
-
If you want a person who always plays it safe, probably they should not work for Genentech
SOURCE: FiercePharma -
We are disappointed that the interim analysis of the phase IIb clinical trial resulted in discontinuation of the study, especially given the unmet medical need for DLBCL patients ... In collaboration with Genentech, we will conduct a detailed analysis of data from the SeaGen MARINER trial.
SOURCE: Xconomy -
Google Inc Chief Executive Eric Schmidt said former Genentech CEO Arthur Levinson should stay on the boards of both Google and Apple Inc, despite regulatory scrutiny
SOURCE: MacDailyNews
– 
